



RECEIVED

NOV 07 2000

TECH CENTER 1600/2800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Daniel E. Afar et al.	Examiner:	Not yet assigned
Serial No.:	09/455,486	Group Art Unit:	1643
Filed:	December 6, 1999	Docket:	G&C 129.17-US-I1
Title:	NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCERS AND USES THEREOF		

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on October 6, 2000.

By: 

Name: Karen S. Canady

Attn: Office of Initial Patent Examination
Customer Service Center
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

We are transmitting herewith the attached:

- ☒ Transmittal sheet, in duplicate, containing a Certificate of Mailing under 37 CFR 1.8.
- ☒ Request for Corrected Filing Receipt and Copy of Filing Receipt.
- ☒ Return postcard.

Please consider this a **PETITION FOR EXTENSION OF TIME** for a sufficient number of months to enter these papers, if appropriate.


Please charge any additional fees or credit any overpayment to Deposit Account No. 50-0494 of Gates & Cooper. A duplicate of this paper is enclosed.

GATES & COOPER
Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, CA 90045
(310) 641-8797

By: 

Name: Karen S. Canady
Reg. No.: 39,927
KSC/amb

(PTO TRANSMITTAL - GENERAL)



FILE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

NOV 07 2000

TECH CENTER 1600/2900

Applicant: Daniel E. Afar et al. Examiner: Not yet assigned
Serial No.: 09/455,486 Group Art Unit: 1643
Filed: December 6, 1999 Docket: G&C 129.17-US-I1
Title: NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN
HUMAN CANCERS AND USES THEREOF

CERTIFICATE OF MAILING OR TRANSMISSION UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on October 6, 2000.

By: 
Name: Karen S. Canady

REQUEST FOR CORRECTED FILING RECEIPT

Attn: Office of Initial Patent Examination
Customer Service Center
Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is a photocopy of the filing receipt from the U.S. Patent and Trademark Office in the above-identified application showing requested corrections. The filing receipt is erroneous in the following respects as reflected in the papers originally filed on April 10, 2000.

The requested correction is shown in **Bold** as follows:

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/323,873 06/01/99

Correction of the records of the U.S. Patent and Trademark Office and issuance of a corrected filing receipt are respectfully solicited.



Date: October 6, 2000


KSC/amb

Respectfully submitted,

Daniel E. Afar et al.

By their attorneys,

GATES & COOPER
Howard Hughes Center
6701 Center Drive West, Suite 1050
Los Angeles, California 90045
(310) 641-8797


By: 

Name: Karen S. Canady

Reg. No.: 39,927

FILING RECEIPT

OC000000005066830


UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office

 Address: ASSISTANT SECRETARY AND
 COMMISSIONER OF PATENT AND TRADEMARKS
 Washington, D.C. 20231
NOV 07 2000
TECH CENTER 1600/2000

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/455,486	12/06/1999	1643	1013	1703-011.US2	37	39	8

KENNETH K SHARPLES
 LAW OFFICE OF KENNETH K SHARPLES
 80 FOURTH STREET
 P O BOX 277
 POINT REYES STATION, CA 94956

Date Mailed: 04/21/2000

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).**

Applicant(s)

DANIEL E. AFAR, Pacific Palisades, CA ;
 RENE S. HUBERT, Los Angeles, CA ;
 ARTHUR B. RAITANO, Los Angeles, CA ;
 DOUGLAS C. SAFFRAN, Los Angeles, CA ;
 STEPHEN C. MITCHELL, Santa Monica, CA ;

Continuing Data as Claimed by Applicant

THIS APPLICATION IS A CIP OF 09/323,873

Foreign Applications
 ↑
 INSERT

If Required, Foreign Filing License Granted 01/11/2000

**** SMALL ENTITY ******Title**

NOVEL SERPENTINE TRANSMEMBRANE ANTIGENS EXPRESSED IN HUMAN CANCERS
 AND USES THEREOF


Preliminary Class

424

Data entry by : JACKSON, MINNIE

- **Team : OIPE**

Date: 04/21/2000



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as **"a," "an" and "the"** are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words **"new," "improved," "improvements in" or "relating to"** are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."

Any corrections that may need to be done to your Filing Receipt should be directed to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231